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Abstract Cellular senescence, which is associated with
aging, is a process by which cells enter a state of permanent
cell cycle arrest, therefore constituting a potent tumor
suppressive mechanism. Recent studies show that, despite
the beneficial effects of cellular senescence, senescent cells
can also exert harmful effects on the tissue microenviron-
ment. The most significant of these effects is the
acquisition of a senescent-associated secretory pheno-
type (SASP), which entails a striking increase in the
secretion of pro-inflammatory cytokines. Here, we
summarize our knowledge of the SASP and the impact
it has on tissue microenvironments and ability to stimulate
tumor progression.
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1 Introduction
Organisms with renewable tissues are at risk for developing
hyperproliferative diseases, the most deadly of which is
cancer. This risk is mitigated by tumor suppressor mecha-
nisms, which suppress cancer for much of the life span.
However, because these mechanisms are imperfect, cancer
still poses a major challenge to the longevity of such
organisms [1, 2]. Some tumor suppressor mechanisms act
by curtailing the acquisition of mutations, either by
preventing DNA damage or optimizing DNA repair. Others
act by preventing damaged or mutant cells from developing
into a tumor by eliminating them entirely (apoptosis) or
permanently arresting their proliferation (cellular senes-
cence). Several lines of evidence suggest that these tumor
suppressor mechanisms can be doubled-edged swords:
whereas they undoubtedly suppress the development of
cancer early in life, they can also result in altered tissue
structure, organization, and homeostasis. These tissue
changes can drive phenotypes and pathologies associated
with aging, including, ironically, late-life cancer.
In support of a role in tumor suppression, cellular
senescence is induced by many potentially oncogenic
stimuli [3–5]. In addition, the senescence response depends
on two potent tumor suppressor pathways: that governed by
the p53 protein and that governed by the pRB and p16
INK4a
proteins. Indeed, germline mutations in p53 or p16
INK4A
allow cells to ignore certain senescence-inducing signals
and greatly increase cancer susceptibility [6, 7]. Further,
virtually all cancers harbor mutations in the p53 and/or p16/
pRB pathways, which, among other activities, are crucial
for the senescence response [8, 9]. Finally, senescent cells
are found in pre-malignant lesions in mice and humans, and
in mouse models, the senescence response prevents
malignant progression [10]. Interestingly, in culture and in
vivo, some tumor cells retain the ability to senesce and do
so in response to DNA damaging chemotherapy; in mouse
models, this response is associated with arrested tumor
progression and eventual regression [11–13].
Consistent with a role in aging, senescent cells accumu-
late with age in many rodent, non-human primate, and
human tissues [14, 15]. Moreover, they are found at sites of
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such as osteoarthritis and atherosclerosis [14] and hyper-
proliferative lesions such as benign prostatic hyperplasia
[16] and melanocytic naevi [17]. A limited number of cell
culture and mouse xenograft studies support the idea that
senescent cells secrete factors that can disrupt tissue
structure and function and promote cancer progression
[18–21]. Recent studies on the senescence-associated
secretory phenotype (SASP) of human and mouse fibro-
blasts show it is conserved across cell types and species and
that specific secreted factors are strong candidates for
stimulating malignant phenotypes in neighboring cells
[22, 23].
The idea that a biological process such as cellular
senescence can be both beneficial (tumor suppressive) and
deleterious (pro-tumorigenic) is consistent with a major
evolutionary theory of aging termed antagonistic pleiotropy
[24]. The SASP may be the major reason for the deleterious
side of the senescence response and is the focus of this
review. We particularly emphasize the potential effects of
the SASP [25] on cell behavior in the context of tumor
progression.
2 Cellular senescence as a stress response
Cellular senescence was first identified as a process that
limits the proliferation of human cells in culture [26]. These
early experiments showed that cultured human fibroblasts
gradually lose proliferative capacity until all cells in the
culture cease division. Much of this growth arrest is known
to occur because most human cells do not express
telomerase. Consequently, with each cell cycle, telomeres
shorten and eventually fail, generating a persistent DNA
damage signal that permanently arrests growth [27]. It is
now known, however, that cellular senescence occurs in
culture and in vivo as a response to excessive intracellular
or extracellular stress (see Fig. 1). The senescence program
locks the cell into a cell cycle arrest that prevents the
damage from affecting the next cell generation, thereby
preventing potential malignant transformation [24]. Senes-
cent cells have been shown to accumulate over the life span
of rodents, non-human primates, and humans and are found
primarily in renewable tissues [15, 28].
Many types of stresses can provoke cellular senescence
[5, 29] (see Fig. 1). These stresses include dysfunctional
telomeres resulting from repeated cell division (replicative
senescence) or other telomeric damage. They also include
oxidative stress resulting from mitochondrial deterioration
or other causes, severe or irreparable DNA damage from
external sources and disrupted chromatin organization due
to DNA replication or damage (genotoxic stress), and the
expression of certain oncogenes (oncogene-induced senes-
cence) [10, 14, 30–35]. Stresses that cause cellular
senescence can be induced by external or internal chemical
or physical insults encountered during the course of the life
span, during therapeutic interventions (for example, X-
irradiation or chemotherapy), or as a consequence of
endogenous processes such as oxidative respiration or
mitogenic signals. External mitogenic signals, for example
growth-related oncogene alpha (GROα) secretion by tumor
cells in close to normal cells [36] or circulating angiotensin
II [37, 38], have also been shown to induce cellular
senescence. All somatic cells that have the ability to divide
can potentially undergo senescence. Regardless of the
disparate mechanisms of senescent-inducing stresses, the
senescence program is activated once a cell has sensed a
critical level of damage or dysfunction. Senescent cells are
detected in culture and in vivo by a variety of markers,
including the senescence-associated β-galactosidase (SA-
βgal) [28], p16
INK4a [39], telomere-associated DNA dam-
age foci [40], senescence-associated heterochromatin foci
[41], and several other molecules; all of these markers have
some limitations, and thus must be used in combination
with each other, as well as proliferation markers (absent in
senescent cells) [42].
3 The secretory phenotype of senescent cells
Cellular senescence is accompanied by a striking increase
in the secreted levels of >40 factors involved in intercellular
signaling [22, 25, 43]. This phenotype has been termed the
“senescence-associated secretory phenotype”,o rS A S P
[22]. The SASP has many of the paracrine effects one
would expect from a pro-inflammatory stimulus, which can
be deleterious if left unchecked (see Fig. 2). For example,
senescent cells promote the proliferation and tumorigenesis
of epithelial cells [18], stimulate angiogenesis [44], trigger
an epithelial to mesenchymal transition, accelerate the
invasion of transformed cells [22], and increase the growth
of xenograft tumors in vivo [19]. Further, the SASP has
been shown to occur after treatment of cancer patients with
DNA damaging chemotherapy [22].
The SASP includes several families of soluble and
insoluble factors. These factors can affect surrounding cells
by activating various cell surface receptors and
corresponding signal transduction pathways that may lead
to multiple pathologies, including cancer. SASP factors can
globally be divided into the following major categories:
soluble signaling factors (interleukins, chemokines, and
growth factors), secreted proteases, and secreted insoluble
components. SASP proteases can have three major effects:
shedding of membrane-associated proteins resulting in
soluble versions of membrane-bound receptors, cleavage/
degradation of signaling molecules, and degradation or
274 Cancer Metastasis Rev (2010) 29:273–283processing of the extracellular matrix. These activities
provide potent mechanisms by which senescent cells can
modify the tissue microenvironment. In the following
sections, we discuss the SASP subsets and some of their
known paracrine effects on nearby cells with an emphasis
on their ability to facilitate cancer progression.
3.1 Soluble factors
The most prominent cytokine of the SASP is interleukin
(IL)-6, a pleiotropic pro-inflammatory cytokine. IL-6
secretion has been shown to increase markedly after DNA
damage- and oncogene-induced senescence of mouse and
human keratinocytes, melanocytes, monocytes, fibroblasts,
and epithelial cells [22, 45–47]. Another interleukin
signaling pathway that is upregulated by senescent cells is
IL-1 [48, 49]. Both IL-1α and β are overexpressed and
secreted by senescent endothelial cells [50], fibroblasts [51,
52], and chemotherapy-induced senescent epithelial cells
[53]. As discussed below, IL-6 and IL-8 expressions depend
on the expression and secretion of IL-1α, indicating a
hierarchy on how SASP components are regulated.
Most senescent cells overexpress IL-8 (CXCL-8), along
with GROα and GROβ (CXCL-1, -2; the murine CXCL-1
Fig. 2 Pro-tumorigenic para-
crine effects of senescent cells.
Senescent stromal fibroblasts
can promote various facets of
cancer progression (right panel).
Pre-neopastic or transformed
epithelial cells are shown in
dark color; senescent cells cells
are represented in dark gray.
Pre-senescent and senesent
fibroblasts secrete SASP factors
that can promote cancer pro-
gression and aggressiveness
Fig. 1 Stimuli that trigger cellular senescence. DNA damage or
mitogenic signals of sufficient magnitude, as well as other stresses,
can cause cells to permanently arrest and senesce. Most of these
senescence inducers lead to the acquisition of multiple senescence
markers (right panel), including the senescence secretory phenotype
(SASP factors). PRE pre-senescent, SEN senescent
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that are generally upregulated in senescent cells are: MCP-
2, -4, -1 (CCL-8, -13, -2), HCC-4 (CCL-16), eotaxin-3
(CCL-26), MIP-3α, and -1α (CCL-20,-3). MCP-3 (CCL-7)
is overexpressed by senescent liver stellate cells and by
prostate and skin fibroblasts. Fibroblasts induced to senesce
by oncogenic RAS secrete high levels of MCP-3, as well as
I-309 (CCL-1).
The insulin-like growth factor (IGF)/IGFR network may
also contribute to the effect senescent cells exert on their
microenvironment. Senescent endothelial, epithelial, and
fibroblast cells express high levels of almost all the IGF-
binding proteins (IGFBPs) including IGFBP-2, -3, -4, -5,
and -6 [22, 55, 56] and their regulators, IGFBP-rP1 and
IGFBP-rP2 (connective tissue growth factor—CTGF) [57,
58]. There are additional soluble factors associated with the
SASP. For example, inflammatory cytokines such as colony
stimulating factors (CSFs including granulocyte-
macrophage (GM)-CSF and G-CSF) are secreted at high
levels by senescent fibroblasts [22].
3.2 Secreted proteases
Aside from soluble signaling cytokines and growth
factors, senescent cells also secrete increased levels of
some matrix metalloproteinases (MMPs). The MMP
family members that are consistently upregulated in
human and mouse fibroblasts undergoing replicative or
stress-induced senescence are stromelysin-1 and -2
(respectively, MMP-3 and -10) and collagenase-1
(MMP-1) [19, 21, 59–61]. In some instances, the MMP-
1 and -3 produced by senescent cells [62] can also regulate
the activity of the soluble factors present in SASP. For
example, these MMPs can cleave MCP-1, -2, and -4 and
IL-8 [63].
Another family of proteases involved in carcinogenesis
and present in the SASP are serine proteases and regulators
of the plasminogen activation pathway: urokinase- or
tissue-type plasminogen activators (uPA or tPA), the uPA
receptor (uPAR), and inhibitors of these serine proteases
(PAI-1 and -2) [64].
3.3 Non-protein secretions
Due to senescence-induced changes in cellular metabolism,
senescent cells may exert influences on tissue microenvir-
onments due to the secretion of molecules other than
proteins. These molecules include reactive oxygen species
(ROS) and transported ions. For example, senescent cells
have been shown to release nitric oxide and ROS due to
alterations in inducible nitric oxide synthase, endothelial
nitric oxide synthase, and superoxide-dismutase activities
[65–69]. These molecules can enhance cancer cell aggres-
siveness, as well as promote aging and age-related
degeneration [70, 71].
4 Regulation of the inflammatory component
of the SASP
Overall, the gene expression profiles (mRNA) of senescent
cells determined by transcript analyses resemble the profiles
of secreted proteins determined by antibody arrays [22, 23].
This finding suggests that the secretory phenotype of
senescent cells is at least in part regulated at the transcrip-
tional level. However, because the changes in gene expres-
sion that occurs at senescence are so widespread, the
transcriptional control may well be at the level of chromatin
organization, rather than changes in specific transcription
factors. In fact, dramatic chromatin alterations are known to
occur at senescence [72–75]. Support for the idea that gene
expression specific to the senescence program may be
partially attributed to larger changes in chromatin conforma-
tion is suggested by the physical clustering of genes that
comprise the SASP [23].
The expressionofmanySASPcomponentsdepends onthe
transcription factors NF-κBa n dC / E B P β, which have
increased activity at senescence [47, 76] (A. Freund and J.
Campisi, unpublished data). Knockdown of C/EBPβ dimin-
ishes the expression of both IL-6 and IL-8, which are among
the most upregulated cytokines at senescence [47], and NF-
κB knockdown significantly decreases the levels of numer-
ous (75%) SASP factors (A. Freund and J. Campisi,
unpublished data).
A surprising recent finding was that the DNA damage
response (DDR) is required for the increased secretion of a
subset of SASP factors, including IL-6 and IL-8 [77]. The
DDR is a signal amplification cascade that senses DNA
damage, inducing cell cycle arrest and initiating DNA
damage repair. If the extent of DNA damage is irreparable,
the cell undergoes cellular senescence but maintains a
chronic, low level DDR [78]. It is this persistent DDR that
is necessary for a robust SASP; depletion of upstream
components of the DDR cascade, specifically ATM, NBS1,
or CHK2, prevents an increase in secreted protein levels of
IL-6, IL-8, and the GRO family, among others.
However, the DDR cannot be the sole regulator of the
SASP because the DDR is activated immediately after
damage, whereas the SASP, like other aspects of the
senescence phenotype such as SA-βgal activity, takes
several days to develop. Additionally, a transient DDR—
for example, caused by a low level of ionizing radiation that
does not induce senescence—does not induce a SASP [77].
Thus, while the DDR is important, it is not sufficient; there
must be other, slower events that cooperate with the DDR
to induce the SASP. One such event is p38MAPK
276 Cancer Metastasis Rev (2010) 29:273–283activation, which increases slowly after DNA damage,
reaching peak levels after several days (A. Freund and J.
Campisi, unpublished data).
Like many cytokine networks, the SASP also has an
important positive-feedback component. IL-1α, a cytokine
that regulates its own synthesis in an autocrine, receptor-
mediated,positive-feedbackloopviaNF-κB[79, 80], is a key
positive regulator of IL-6 and IL-8 expression at senescence
[81]. IL-1α depletion by RNAi in senescent cells markedly
reduced the extracellular protein levels of IL-6 and IL-8.
Similar results were achieved using an IL-1 receptor (IL-1R)
antagonist or neutralizing antibodies, demonstrating that
sustained IL-1R stimulation by surface-bound IL-1α is
required to maintain senescence-associated IL-6 and IL-
8 extracellular levels [81].
MicroRNAs also play a role in SASP regulation. Thus
far, two microRNAs, miR-146a and miR-146b (miR-146a/b),
have been demonstrated to negatively regulate the
senescence-associated secretion of IL-6 and IL-8 [82]. Senes-
cent human fibroblasts with a strong SASP upregulate these
microRNAs late in senescence, tuning down the secretion of
inflammatory cytokines. IRAK1 is an established target of
miR-146a/b and is indeed targeted in senescent cells,
suggesting that these microRNAs downregulate the SASP
by reducing NF-κBa c t i v i t y[ 83]. When miR-146a/b are
overexpressed in human fibroblasts, IRAK1 levels decline,
along with the enhanced secretion of senescence-associated
IL-6/IL-8. In addition, blockage of IL-1 receptor signaling
prevented upregulation of miR-146a/b, consistent with these
microRNAs being part of an NF-κBf e e d b a c kl o o p[ 83].
These data once again highlight the important role of NF-κB,
and place miR146a/b as central players of IL-6 and IL-
8 secretion within the SASP.
Although the SASP is at least partly regulated by the
activation of transcription factors, the general gene expres-
sion profile acquired at senescence may be more attribut-
able to the larger changes in chromatin conformation that
senescent cells develop [72–74, 84]. Consistent with this
idea is the physical clustering of SASP genes such as
matrix metalloproteinases (MMP-1, MMP-3, MMP-10, and
MMP-12) as well as CXCL and CCL family members [23].
Moreover, recent work indicates the key role for the High
Mobility Group Box 1 protein (HMGB1) in senescent cells.
5 HMGB1 regulates senescence-associated
inflammatory cytokine secretion
HMGB1 is a member of the non-histone, chromatin-
binding high mobility group family of proteins [85]. Unlike
histones, HMGB1 loosely binds the minor grove of DNA,
stabilizing nucleosome formation, thereby influencing the
expression of certain genes [86–88]. HMGB1 was shown to
directly interact with p53, and recombinant HMGB1
protein enhanced p53 DNA binding in vitro [89].
The discovery that necrotic cells, but not apoptotic cells,
passively release HMGB1 focused recent studies on the
role of extracellular HMGB1 [90]. Initial studies suggested
that extracellular recombinant HMGB1 promoted secretion
of inflammatory cytokines (TNFα, IL-1β, and IL-6) by
macrophages [91]. However, later work revealed that
recombinant HMGB1 protein alone exhibited only weak
activity, but synergized with the ability of bacterial
components like lipopolysaccharides to stimulate inflam-
matory cytokine secretion [92, 93]. Further, HMGB1 can
enhance the pro-inflammatory activity of cytokines [94].
These findings appear in conflict with those showing that
anti-HMGB1 antibodies or antagonist reduced inflamma-
tion in arthritis models [95]. However, the general
consensus now is that HMGB1 alone may not promote
inflammation, but rather augment the inflammatory re-
sponse in certain biological contexts.
While it was not observed that cells cultured with
recombinant HMGB1 stimulated cytokine secretion, extra-
cellular HMGB1 may enhance of the effect of the SASP (A.
Davalos and J. Campisi, unpublished data). Similar to
recent data showing that apoptotic cells release “find-me
signals”, which recruit innate immune to clear the dying
cells, senescent cells also secrete HMGB1, known to recruit
and activate cells from the innate immune system [96]. This
notion is consistent with two studies that suggest senescent
cells may undergo clearance in vivo [13, 97].
Despite the obvious benefit of recruiting and activating
innate immune cells to clear senescence cells, extracellular
HMGB1 protein may promote cancer and metastatic progres-
sion. Experiments in cell culture showed that HMGB1
stimulated the migration of neuroblastoma cells, which was
attenuated by an antibody against HMGB1 [98]. Further, in
an in vitro angiogenesis assay, HMGB1 stimulated sprouting
of endothelial [99]. When immunocompromised mice were
injected with rat glioma cells, followed by injection with
anti-RAGE (a HMGB1 receptor) or anti-HMGB1 antibodies,
both antibodies individually reduced tumor volume, but
maximal reduction occurred with both antibodies [100].
Thus, extracellular HMGB1 is able to provoke both
beneficial and deleterious biological consequences. It may
act to alert and identify senescent cells that require clearance.
Failure to clear all senescent cells could leave sites of
persistent secretion of inflammatory molecules.
6 Senescent cells create a permissive microenvironment
allowing cancer cells to thrive
Inflammation has been shown to initiate or enhance several
age-related diseases, including atherosclerosis, Alzheimer’s,
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senescent cells can promote tumor development in vivo and
malignant phenotypes such as proliferation and invasive-
ness in cell culture models. These effects have been
observed with a number of cell types, including cells
derived from breast [18, 19, 21, 22, 104], skin [105],
prostate [22, 106], pancreas [107], and oro-pharyngial
mucosa [108]. The effects of the complex SASP is, of
course, dependent on the tissue context. In the following
sections, we present the various behavioral changes cells
can undergo when residing in the proximity of senescent
cells and discuss how the senescent tissue microenviron-
ment can facilitate tumor initiation and progression (see
Fig. 2).
6.1 Effects on cell proliferation
One of the most direct, pro-tumorigenic effects of the SASP
is to promote the proliferation of epithelial cells. In the case
of breast epithelial cells, senescent human fibroblasts can
stimulate the growth of pre-malignant and malignant
mammary epithelial cells [18, 21, 22]. Irradiated stromal
cells, which are presumed to be senescent, have been
shown to perturb the mammary epithelial microenviron-
ment and fuel inappropriate epithelial cell growth in the
mammary gland [104, 109]. Furthermore, MMPs secreted
by senescent fibroblasts have been shown to be responsible
for the higher tumorigenicity of breast epithelial cell
xenografts in mice, most likely by allowing mitogenic and
chemotactic signals greater access to breast cancer cells [19,
104]. In addition to secreted soluble factors, there is
evidence that the matrix laid down by senescent cells can
also stimulate mammary epithelial cell growth [18].
Fibroblasts from the human prostate gland that undergo
senescence in culture have been shown to create a local
tissue environment that favors prostate epithelial cell
hyperproliferation, in part owing to amphiregulin secretion
[20]. Furthermore, senescent fibroblasts increase the ex-
pression of CTGF (or IGFBPr2) [58]. CTGF was shown to
promote prostate tumor progression in xenografts and is
also expressed by the cancer-associated reactive stroma
[110]. Moreover, it was recently determined that senescence
induced by irradiation in prostate cancer patients was
associated with a significantly increased release of
exosome-like microvesicles [111]. This novel secretory
phenotype was dependent on the activation of p53.
In the skin, unidentified factors secreted by human
fibroblasts were shown to be capable of inducing clonal
expansion of keratinocytes [112]. In addition, senescent
endometrial fibroblasts promoted anchorage-independent
epithelial cell growth, due primarily to IL-1 oversecretion
[52]. In the oro-bucal cavity, tobacco-driven senescence of
supportive stromal cells was shown to stimulate the
hyperplastic growth of epithelial cells and was associated
with the loss of E-cadherin, ZO-1, and involucrin as well as
with the loss of epithelial integrity [108].
Melanocytic naevi (moles) are often composed of
senescent melanocytes, which were induced to senesce
by oncogenic mutations in BRAF (V600E mutations)
[17]. Only rare cell variants in naevi can evolve into
melanoma. Malignant melanocytes express high levels of
the CXCR2 receptor [113] and can be stimulated to grow
by its ligands GROα [114]o rI L - 8[ 115]. Given that both
GROα and IL-8 are part of the core SASP, the senescent
microenvironment may therefore stimulate the prolifera-
tion of rare pre-malignant cells in naevi and thus drive the
development of melanoma.
Endothelial cells can undergo proliferation during
angiogenesis, which is stimulated by vascular endothelial
growth factor (VEGF), IL-8, I-309, and eotaxin [44, 116,
117], all of which are SASP components. Indeed, senescent
cells can stimulate endothelial cell migration in culture and
angiogenesis in vivo in mouse xenografts of breast cancer
cells. The blood vessel density was significantly higher
when tumors developed in the presence of senescent, but
not pre-senescent, fibroblasts [44]. RAS-driven tumors are
also known to contain significant numbers of senescent
cells [118]. These tumors are also highly vascularized
[119]. Many of the SASP factors can also affect leukocyte
proliferation during the course of cancer development. For
example, IL-7 directly promotes lymphocyte proliferation
in peripheral tissues, and GM-CSF stimulates myeloid
suppressor cells, which are known to have important
immunosuppressive functions that affect cancer progression
[120].
6.2 Effects on cell migration and invasion
Senescent cells oversecrete an array of chemokines that
can create a gradient to promote cell migration and
invasion. In pancreatic cancer, hepatocyte growth factor
(HGF), and to a lesser degree bFGF, promote cancer cell
invasion in culture and potentially can drive cancer
dissemination in vivo [107, 121]. In breast cancer, high
levels of IL-6 and -8 secreted by senescent fibroblasts are
responsible for enhancing the invasiveness of a panel of
cancer cell lines in cell culture models [22]. Moreover, the
secretion of MMP-2 and -3 by senescent cells can also
promote the invasion of multiple epithelial cell types [19,
21, 104, 122, 123]. Other proteases, such as uPA and its
regulator (PAI1), are likewise implicated in cancer cell
invasion. Senescent stromal cells may promote an
epithelial-to-mesenchymal transition (EMT) [22], which
is an important phenotypic switch that enables cancer cells
to migrate and invade [108]. Thus, senescent cells and the
SASP can induce phenotypes in nearby human epithelial
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aggressive phenotype in tumors.
In cell culture models, endothelial cells are induced to
migrate by factors secreted by senescent fibroblasts [44].
This is in part due to VEGF secretion and chemokine
gradients set up by senescent cells [124]. Neo-angiogenesis,
which is dependent on endothelial cell motility and
invasion, is enhanced in xenograft models containing
senescent fibroblasts [44]. Further, it is known that IL-1,
which is a SASP component, activates the endothelium and
consequently increases the adhesive potential of cancer
cells to vessel walls [125]. Thus, senescent cells might
promote extravasation of cancer cells to secondary meta-
static sites. However, the effects of senescent cells on
angiogenesis might be cell-type dependent. For example,
senescent keratinocytes oversecrete maspin, which acts as a
dominant inhibitor of endothelial cell migration and
invasion [126].
Senescent fibroblasts may promote leukocyte recruit-
ment, since they chronically release chemokines [127]. In
p53-deficient RAS-driven tumors induced to senesce by
reestablishing p53 function [13], innate immune cells were
shown to migrate into the vicinity of the senescent tumor
area. CSF-1, CXCL-1, or MCP-1 and ICAM-1 transcripts
were found to be higher in these senescent tumor masses
and may be responsible for the immune response. For
example, neutrophils express CXCR-1, -2, and -4 to sense
their microenvironment and invade tissues; eosinophils use
the broad spectrum receptor CCR-3 to fulfill their function;
monocytes use CCR-1, -2, -5, CXCR-4, and CX3CR1 to
extravasate and enter peripheral sites where they differen-
tiate; natural killer cells express CCR-2, -5, CXCR-4,
CX3CR1, and XCR1; and immature myeloid dendritic cells
display CCR-1, -2, -5, -6, and CXCR-4, which facilitate
their transport, migration, and function [127–130].
6.3 Effects on cell differentiation
Senescent human and mouse fibroblasts disrupt the differ-
entiation of mammary epithelial cells and inhibit the
expression of differentiation markers [21, 104]. This
activity is due in large measure to the secretion of MMP-
3 by the senescent cells. Furthermore, weakly tumorigenic
pancreatic [107] and mammary [22] epithelial cells undergo
morphologic changes in culture resembling an EMT in the
presence of senescent conditioned medium. The effect on
mammary epithelial cells is attributable to IL-6 and IL-
8[ 22], as well as HGF, uPAR, and MMPs [21], which are
all capable of disrupting epithelial cell clusters and
stimulating de-differentiation in culture and in vivo [131–
133].
Strikingly, no angiostatic factors have been reported
among SASP constituents (for example, IFNγ, TSP-1,
MIG, PF4, IP-10, IL-4, IL-12, and endostatin). This
contrasts with the largely pro-angiogenic profile of the
SASP (IL-8, MCP-1 and -2, GROs, PGE2, VEGF, EGF,
CSFs, uPA/tPA, MMPs, FN, and laminin) [134]. Further-
more, there may be an amplifying activation loop since
senescent stromal cells secrete MCPs, CSFs, MIPs, GROs,
and CXCLs, which in turn recruit inflammatory and
immune cells that also secrete pro-angiogenic factors
(VEGFs, IL-8, and MMPs). Thus, senescent cells are well
poised to support the differentiation of a new vasculature
around and within a progressing tumor.
6.4 Effects on tumor immunology
No anti-inflammatory factors (e.g., IFNα, IFNγ, IL-3, IL-5)
are significantly secreted by senescent fibroblasts, and some
of these factors are even downregulated upon senescence
(e.g., IL-2, IL-12). Nonetheless, some reports show that
massive amounts of MCP-1 or IL-8, which are prominent
components of the SASP, lead to tumor destruction [135,
136]. Senescent fibroblasts might influence the macrophage
balance in the tumor environment. Molecules that are
implicated in the recruitment and differentiation of circu-
lating monocytes to tumor sites also happen to be overex-
pressed by senescent fibroblasts [137]. These molecules can
lead to an inadequate immune response within the close
proximity of senescent cells. Senescent fibroblasts might
affect lymphocytic populations infiltrating the tumor.
Specific T-cell populations associated with tumor progres-
sion (i.e., Th2 and T-reg) respond to inflammatory
cytokines that are commonly present in the SASP of
fibroblasts.
7 Conclusions
From the above discussion, the SASP may play an
important role in senescence, especially in the days
immediately after senescence induction, by helping the
growth arrest to occur efficiently and the immune system to
target senescent cells for clearance. However, senescent
cells appear to accumulate in vivo despite clearance,
suggesting that either the clearance is not 100% efficient,
or the rate of senescence increases with age, outpacing the
rate of clearance. Consequently, the SASP’s deleterious,
chronic inflammatory effects may only become apparent
with time. It is therefore important to understand the
pathways that regulate the SASP, to determine how it can
be modulated and whether the potentially deleterious
effects of the SASP can be inhibited without sacrificing
the beneficial effects of senescence.
Most insoluble components of the extracellular matrix
(ECM) are enzymatic targets of secreted proteases. There-
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activities could affect the physical properties of the tissue
structure around cells. In particular, the accumulation of
senescent cells could lessen the supportive role of the ECM,
globally diminishing tissue tension and elasticity. In
addition, the relaxed tissue structure and higher levels of
MMPs might help tumor cells migrate and invade through
the ECM, thus enabling metastasis. In fact, the panel of
proteases secreted by senescent cells extensively overlaps
with those found in malignant tumors.
Overall, senescence is a molecular program with a unique
phenotypic outcome. How its extracellular molecular signa-
ture is activated and maintained, and the extent to which it
influences the tissue milieu in healthy tissues, aged tissues,
and diseased tissues, are some of the many questions that
remain unanswered. However, even with our current limited
knowledge of the senescent secretory phenotype and its
potential effects on carcinogenesis, promising new strategies
for cancer therapies emerge. For example, restoring the
activity of tumor suppressor genes is an attractive, potentially
powerful therapeutic approach. Taking into account our
current understanding of the cell’s non-autonomous effects
of these tumor suppressor genes, small chemicals that can
pharmacologically restore their normal function would help
reestablish the proper tissue and cell signals, thereby
stimulating cancer regression [138–141]. Such approaches
would limit inflammation and thus possibly allow proper
tissue repair, and they would directly promote the immune-
mediated clearance of cells that drive cancer progression.
Chronic inflammation, once established, often takes on a
momentum of its own due to the feedback loops of the
immune system: cytokines activate leukocytes, which
produce more cytokines [142]. Therefore, even a small
pro-inflammatory stimulus, such as a population of senes-
cent cells scattered throughout organs and tissues, could be
the seed for a more systemic chronic inflammatory response
over time, leading to age-related diseases such as cancer.
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